Lentiviral-mediated Gene Therapy of Fanconi Anemia Patients Subtype A
Condition: Fanconi Anemia Interventions: Procedure: IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs); Biological: Genetically Engineered Hematopoietic Stem/Progenitor Cells; Other: Laboratory Biomarker Analysis; Biological: Filgrastim; Drug: Plerixafor; Procedure: Bone Marro w Aspiration Sponsors: Hospital Infantil Universitario Niño Jesús, Madrid, Spain; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas (CIEMAT); Centro de Investigación en Red de Enfermedades Raras (CIBERER); Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz; Hosp ital Vall d'Hebron; Universitat Autonoma de Barcelona Recruiting - verified May 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Anemia | Faconi Anemia | Filgrastim | Gene Therapy | Genetics | Hospitals | Neulasta | Neupogen